BRAF and neoplasm: Even where there is a dramatic effect on the tumour and extension of patient survival, the focus on a single molecular pathway appears to invite rapid acquisition of resistance in the tumour cells through activation of alternate signalling pathways (e.g. BRaf inhibitor in melanoma, which brings dramatic initial results but quickly elicits resistance) [4].